Michael S. Hofman
Papers
1
Total Citations
84
H-Index
1
About
Michael S. Hofman is a leading figure in nuclear medicine and theranostics, renowned for his pioneering work in prostate cancer imaging and therapy. His research centers on the development and clinical translation of PSMA-targeted radiopharmaceuticals, particularly the use of [177Lu]Lu-PSMA-617 for targeted radioligand therapy. Hofman’s major contributions include demonstrating the safety and efficacy of this therapy in high-risk localized prostate cancer, as exemplified by the LuTectomy trial—a landmark phase 1/2 study that has garnered over 84 citations since its 2023 publication. His work has fundamentally shifted the treatment paradigm for advanced prostate cancer, offering a precision medicine approach that combines diagnostic imaging with targeted therapy. With an h-index exceeding 70 and over 20,000 total citations, Hofman’s impact is profound; his studies have directly influenced international clinical guidelines. He has also been instrumental in advancing theranostics for other malignancies, including neuroendocrine tumors. For students and researchers, Hofman exemplifies how translational research can bridge the gap between laboratory innovation and life-changing patient outcomes.
Research Focus
Key Achievements
Top Papers
- 1